HUTCHMED Doses First Patient in Global Phase Ia Trial of KRAS-EGFR Antibody-Targeted Therapy Conjugate HMPL-A830
核心洞察
HUTCHMED has initiated the Phase Ia dose escalation part of a global first-in-human trial of HMPL-A830 (搜索) in unresectable, advanced or metastatic solid tumors, with the first patient dosed in China on September 24, 2026.
HMPL-A830 (搜索) is a first-in-class antibody-targeted therapy conjugate pairing a selective KRAS (搜索) small molecule inhibitor payload with an anti-EGFR (搜索) antibody to block both EGFR and KRAS signaling.
The multicenter, open-label Phase I study will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with dose escalation followed by dose expansion in selected solid tumors.
HUTCHMED has initiated the Phase Ia part of a global clinical trial of HMPL-A830 (搜索) in patients with unresectable, advanced or metastatic solid tumors. The first patient received the first dose in China on September 24, 2026.
HMPL-A830 (搜索) is a first-in-class antibody-targeted therapy conjugate (ATTC) that comprises a highly selective and potent KRAS (搜索) small molecule inhibitor payload conjugated to an anti-EGFR (搜索) antibody. The design is intended to deliver a KRAS inhibitor directly to EGFR-expressing tumors while simultaneously blocking EGFR and KRAS signaling, with the aim of enhancing efficacy, durability and tolerability.
Trial Design and Endpoints
The study is a first-in-human, multicenter, open-label Phase I trial evaluating the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HMPL-A830 (搜索). It consists of a Phase Ia dose escalation part to determine the maximum tolerated dose and the recommended dose for expansion. A subsequent dose expansion and optimization part is designed to further characterize safety, tolerability and preliminary anti-tumor activity in selected solid tumors. Additional details are available at clinicaltrials.gov under identifier NCT07718581.
Rationale for Dual EGFR and KRAS Targeting
Colorectal, pancreatic and lung cancers have the highest incidence of patients with KRAS (搜索)-altered tumors, who often lack a safe and durable KRAS therapy, according to HUTCHMED. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer (搜索), 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma (搜索) patients. KRAS regulates key downstream pathways, including RAS/MAPK and PI3K/AKT/mTOR, to drive cell differentiation, proliferation and survival.
While recent targeted therapies have validated KRAS (搜索) as a therapeutic target, significant clinical gaps persist, particularly for patients with non-G12C mutations. Most patients eventually experience disease progression driven by acquired resistance, largely fueled by upstream receptor tyrosine kinase upregulation and secondary KRAS alterations. Beyond mutation coverage, systemic delivery of pan-KRAS and pan-RAS inhibitors is associated with on-target toxicities, such as dermatological toxicity reflecting RAS pathway inhibition in normal tissue. These present challenges for dosing, long-term tolerability, and combination with cytotoxic chemotherapy or immunotherapy backbones that constitute frontline standard of care.
EGFR (搜索) is a widely expressed receptor tyrosine kinase and an established driver of tumor cell proliferation, survival and disease progression across multiple solid tumors, including colorectal cancer (搜索), pancreatic ductal adenocarcinoma (搜索) and non-small cell lung cancer (搜索). Signaling through EGFR activates the downstream RAS/MAPK and PI3K/AKT/mTOR pathways, positioning the receptor immediately upstream of KRAS (搜索). EGFR has also emerged as a key mediator of resistance to KRAS-targeted therapies, particularly in colorectal cancer, where adaptive feedback and increased upstream EGFR signaling reactivate the MAPK pathway and limit the depth and durability of KRAS inhibition. HUTCHMED states that these findings provide a strong rationale for dual targeting of EGFR and KRAS in colorectal cancer as well as additional indications such as pancreatic and lung cancers.
The ATTC Platform
HUTCHMED describes its ATTCs as a next-generation approach to precision oncology that combines monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action. Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in both efficacy and safety, according to the company.
The company states that the ATTC platforms, built on more than 20 years of targeted therapy expertise, enable development of drug candidates across diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve accessibility to tumors and reduce off-tumor toxicity. This may overcome the on-target, off-tumor toxicity limitations of systemically delivered small molecule inhibitors, which in turn could support safer long-term use and combinations with chemotherapy and immunotherapy in earlier-line treatments.
GSK License Agreement
On September 3, 2026, HUTCHMED Limited, a subsidiary of the company, entered into an exclusive development and license agreement with a subsidiary of GSK plc. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830 (搜索). HUTCHMED Limited is responsible for the global Phase I development program of HMPL-A830, while the GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside Mainland China, Hong Kong, Macau and Taiwan. The agreement is subject to customary closing conditions, including completion of any antitrust regulatory reviews.
HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, global development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Its first four medicines are marketed in China, and the first of these is also approved in the United States, Europe and Japan.